Two drug molecules approved for type 2 diabetes now shape business decisions well beyond the pharmacy counter, touching ten industries from contract manufacturing to restaurants — with sharply uneven effects.

Semaglutide and tirzepatide belong to a class called GLP-1 drugs (medicines that mimic glucagon-like peptide-1, a hormone the gut releases). Novo Nordisk sells semaglutide as Ozempic for diabetes and Wegovy for weight management. Eli Lilly sells tirzepatide as Mounjaro and Zepbound. The FDA approved Ozempic in December 2017, Wegovy in June 2021, Mounjaro in May 2022 and Zepbound in November 2023. In 2024, regulators widened the pool again: Wegovy for cardiovascular risk reduction in March, Zepbound for obstructive sleep apnea in December.

Who gains directly?

Drugmakers lead. Novo's March 2024 Wegovy approval, for cutting the risk of cardiovascular death, heart attack and stroke in adults with established cardiovascular disease plus obesity, rested on its SELECT outcomes trial. Zepbound became the first drug approved to treat moderate-to-severe sleep apnea in adults with obesity. Pressure remains: the two companies compete for the same patients, U.S. payers scrutinize prices, and rivals are developing their own obesity treatments.

Contract manufacturers with sterile fill-finish capacity (the final stage where injectable drugs are filled into vials, syringes or cartridges under sterile conditions) also gain. Novo Holdings, Novo Nordisk's controlling shareholder, closed its $16.5 billion purchase of Catalent in December 2024. As part of that deal, Novo Nordisk paid $11 billion for three Catalent fill-finish sites. The driver was demand for injectable pen capacity, which cannot be swapped in quickly because filling lines run inside regulated clean rooms.

Who lost the shortage window?

Telehealth companies and compounding pharmacies had mixed results. FDA shortage listings let compounders copy semaglutide and tirzepatide. The FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025. Once each drug left the list, the legal basis for large-scale copying disappeared. Novo Nordisk ended a partnership with Hims & Hers, which had sold compounded semaglutide via telehealth. Telehealth providers can still prescribe branded drugs, and pharmacies can still compound for individual patients under normal rules.

What happened to Weight Watchers?

WW International filed for Chapter 11 bankruptcy protection in May 2025 and emerged in July 2025. The company had built its business on behavior change — meal plans, tracking, group meetings — and GLP-1 drugs gave dieters a prescription alternative. WW bought the telehealth clinic Sequence in 2023, after Wegovy launched and before Zepbound, to connect members with prescribing clinicians. The filing doesn't prove the drugs alone caused its troubles; debt and competition also weighed. The timeline does show the drugs reshaped a market WW had served for decades.

Are food and alcohol sales really at risk?

For packaged food makers, the evidence points in one direction but stays thin. A Cornell University and Numerator analysis found households lowered grocery spending after one member started a GLP-1 drug. It doesn't measure any single company's revenue at risk, or whether the change lasts. Duration matters: in the extension of Novo's STEP 1 trial, participants who stopped semaglutide regained most of their lost weight within a year. Some food companies now market products stressing protein, fiber and smaller portions to GLP-1 users.

Alcohol is even less settled. In 2025, Gallup reported that 54% of U.S. adults said they drink alcohol — the lowest share recorded since the question was first asked in 1939. The timing invites comparison, but overlapping timelines don't establish cause. Researchers are testing whether GLP-1 drugs could treat alcohol use disorder, but none of the four brands carries FDA approval for it.

What about surgery and sleep devices?

Bariatric surgery now has a prescription rival. Sleeve gastrectomy removes most of the stomach; Roux-en-Y gastric bypass creates a small pouch connected directly to the lower intestine. The biology overlaps: gastric bypass raises the body's own GLP-1 levels after meals. The trade-offs differ — surgery is one-time, while a GLP-1 prescription is billed weekly for as long as a patient stays on it. Some clinicians now prescribe the drugs to patients who regain weight after surgery.

For CPAP makers such as ResMed, the effect is disputed. One argument holds weight loss could reduce machine use; another holds drug attention could send more undiagnosed people to sleep testing, and some onto CPAP. Patients can use both.

Who pays for all this?

Employers, insurers and Medicare sit on the cost side. By law, Medicare Part D cannot cover drugs used only for weight loss — but prescriptions for diabetes or cardiovascular risk reduction fall outside that exclusion, and the same molecule can sit inside or outside coverage depending on diagnosis. The North Carolina State Health Plan ended GLP-1 weight-loss coverage in 2024. Weekly injections mean each covered member becomes a repeating expense.

Restaurants face a possible loss: a diner who feels full sooner orders fewer appetizers, desserts and drinks. No verified, dated data yet shows how much restaurant spending has changed. The open questions everywhere are uptake and duration — how many people take the drugs, and for how long.